Susanna Grassi

Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

Sara Galimberti, Stefano Luminari, Elena Ciabatti et al. · Clinical Cancer Research · 2014 · 112 citations · Full text

Hematological Malignancy, Pcr Status, Mrd Negativity +13

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

Antonello Di Paolo, Marialuisa Polillo, Matteo Capecchi et al. · The Pharmacogenomics Journal · 2014 · 48 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, G Polymorphism +8

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

Sara Galimberti, Mario Petrini, Claudia Baratè et al. · Frontiers in Oncology · 2020 · 43 citations · Full text

The CoV-2 outbreak: how hematologists could help to fight Covid-19

Sara Galimberti, Chiara Baldini, Claudia Baratè et al. · Pharmacological Research · 2020 · 42 citations · Full text

Virus Epidemiology, Cov-2 Outbreak, Covid-19 Pandemic +6

Real‐Time <scp>PCR</scp> and Droplet Digital <scp>PCR</scp>: two techniques for detection of the <i><scp>JAK</scp>2</i>^<i>V617F</i> mutation in Philadelphia‐negative chronic myeloproliferative neoplasms

Giulia Fontanelli, Claudia Baratè, Elena Ciabatti et al. · International Journal of Laboratory Hematology · 2015 · 34 citations